Literature DB >> 8256506

A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene.

E D Williamson1, R W Titball.   

Abstract

Fragments of the alpha-toxin of Clostridium perfringens have been produced using genetic manipulation techniques. Antibody which cross-reacted with the alpha-toxin was induced after immunization with fragments representing the N- (Cpa1-249) and C-terminal (Cpa247-370) domains of the toxin. Smaller fragments of the alpha-toxin did not induce cross-reacting antibody. Anti-Cpa1-249 serum neutralized phospholipase C activity but not haemolytic activity of the toxin. Anti-Cpa247-370 serum neutralized both the phospholipase C and haemolytic activities. Only immunization with Cpa247-370 induced protection against the lethal effects of the toxin. Immunization with Cpa247-370 also provided protection in a mouse model against at least 10 LD100 doses of C. perfringens type A. This result confirms the essential role of this toxin in the pathogenesis of gas gangrene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8256506     DOI: 10.1016/0264-410x(93)90051-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases.

Authors:  H Schoepe; C Pache; A Neubauer; H Potschka; T Schlapp; L H Wieler; G Baljer
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Clostridium sordellii phospholipase C: gene cloning and comparison of enzymatic and biological activities with those of Clostridium perfringens and Clostridium bifermentans phospholipase C.

Authors:  Tadahiro Karasawa; Xingmin Wang; Tsuneo Maegawa; Yoshio Michiwa; Hiroyuki Kita; Koichi Miwa; Shinichi Nakamura
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

3.  A Recombinant Probiotic, Lactobacillus casei, Expressing the Clostridium perfringens α-toxoid, as an Orally Vaccine Candidate Against Gas Gangrene and Necrotic Enteritis.

Authors:  Mojtaba Alimolaei; Mehdi Golchin; Jalil Abshenas; Majid Ezatkhah; Mehrdad Shamsaddini Bafti
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

Review 4.  Towards an understanding of the role of Clostridium perfringens toxins in human and animal disease.

Authors:  Francisco A Uzal; John C Freedman; Archana Shrestha; James R Theoret; Jorge Garcia; Milena M Awad; Vicki Adams; Robert J Moore; Julian I Rood; Bruce A McClane
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

5.  The virR/virS locus regulates the transcription of genes encoding extracellular toxin production in Clostridium perfringens.

Authors:  W Ba-Thein; M Lyristis; K Ohtani; I T Nisbet; H Hayashi; J I Rood; T Shimizu
Journal:  J Bacteriol       Date:  1996-05       Impact factor: 3.490

Review 6.  Clostridial enteric diseases of domestic animals.

Authors:  J G Songer
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 7.  Potential role of phospholipases in virulence and fungal pathogenesis.

Authors:  M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  Perfringolysin O expression in Clostridium perfringens is independent of the upstream pfoR gene.

Authors:  Milena M Awad; Julian I Rood
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

Review 9.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  Highly conserved alpha-toxin sequences of avian isolates of Clostridium perfringens.

Authors:  Scott A Sheedy; Aaron B Ingham; Julian I Rood; Robert J Moore
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.